Suzhou Zelgen BiopharmaceuticalsLtd Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Zelin Sheng
Chief executive officer
CN¥2.8m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 23.5% |
| Management average tenure | no data |
| Board average tenure | 2.6yrs |
Recent management updates
Recent updates
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Earnings Haven't Escaped The Attention Of Investors
Nov 27
Some Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Analysts Just Made A Major Cut To Next Year's Estimates
Sep 11What Does The Future Hold For Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266)? These Analysts Have Been Cutting Their Estimates
May 08Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Shares Climb 28% But Its Business Is Yet to Catch Up
Mar 06CEO
Zelin Sheng (64 yo)
no data
Tenure
CN¥2,759,100
Compensation
Mr. Zelin Sheng is Chairman of the Board and General Manager of Suzhou Zelgen Biopharmaceuticals Co., Ltd. He has Doctorate in Pharmacology and M.B.A. from China Europe International Business School in Chi...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & GM | no data | CN¥2.76m | 23.5% CN¥ 3.8b | |
| Executive VP & Director | no data | CN¥1.67m | 4.77% CN¥ 770.3m | |
| Director & Deputy GM | no data | CN¥2.35m | 0.013% CN¥ 2.1m | |
| Deputy General Manager & Director | 2.6yrs | CN¥2.06m | 0.013% CN¥ 2.2m | |
| Independent Director | no data | CN¥264.00k | no data | |
| Independent Director | no data | CN¥132.00k | no data | |
| Independent Director | 2.6yrs | CN¥132.00k | no data | |
| Supervisor | 2.6yrs | no data | 0.00028% CN¥ 45.2k |
2.6yrs
Average Tenure
58yo
Average Age
Experienced Board: 688266's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 09:56 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ziyu He | China International Capital Corporation Limited |
| Shitong Han | Citic Securities Co., Ltd. |
| Yinhao Tang | Citic Securities Co., Ltd. |